Refining the HIV Research Enterprise

New opportunities for innovation and discovery in HIV research are within our grasp. Over the next 3 years, the National Institutes of Health will refine its science-driven HIV research enterprise to deliver the innovative, efficient results needed to turn the corner on the HIV/AIDS pandemic.

Every 7 years, NIH competitively renews its funding of the HIV clinical research networks operating in the United States and internationally. NIH is taking a proactive approach to refining the research enterprise and driving HIV discovery. By establishing a forward-looking agenda to guide this process, NIH will determine the focus and priorities of its HIV clinical trial networks through 2027.   Learn more with resources available on this site. Submit your thoughts, perspectives, and questions to NIH online

Information on HIV/AIDS Clinical Trials Network Protocol Funding Pilot Tests

Messages from NIAID

Thought Starter: Filling the Gaps in HIV Prevention Research

By Carl W. Dieffenbach, Ph.D., director, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health

May 12, 2017

Since the previous round of renewals for the NIH clinical trials networks, the approach to global HIV prevention has been marked by dramatic change. The ambitious scale-up of treatment and new options for prevention have transformed the HIV landscape both for those at risk of acquiring the disease and for researchers investigating new ways to prevent HIV infection. Read the complete blog post.

Older posts:

Conversation Starters: How to Turn the Corner on the HIV/AIDS Pandemic - March 20, 2017

Turning the Corner on the HIV/AIDS Pandemic: Refining the Science-Driven HIV Clinical Research Enterprise - February 7, 2017

 

Video: Dr. Carl Dieffenbach talks about refining NIH’s HIV research enterprise 

Video: Archived Presentation: Refining the Science-Driven HIV Research Enterprise 

Content last reviewed on May 12, 2017